ArticleVirchows Archiv : an international journal of pathology2025
No increase of targetable oncogenic fusions prevalence in non-colorectal mismatch repair-deficient tumors.
Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Mismatch repair deficiency is a well-described mechanism of carcinogenesis, which can be identified by microsatellite instability (MSI). In colorectal cancers (CRC), cases with hypermethylation of the MLH1 promoter with wild-type (WT) BRAF /RAS status show a high prevalence of oncogenic fusions, notably those involving NTRK. NTRK fusions can be targeted by TKIs. In CRC, MSI phenotype combined with WT BRAF/RAS status allows for improved screening of patients who could benefit from this treatment. In this study, we aimed to verify if the correlation observed in CRC was valid for other MSI tumors and if this screening method could thus be extended to other cancers. We conducted an analysis on a control cohort of 23 selected CRC and identified 5 fusions, 4 of which involved NTRK1. However, no fusions were found in the cohort of 100 non-colorectal MSI tumors.
Indexed as
Identifiers
41114791What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.